USFDA Nod to Lupin to Market Tablets Used For Treatment of HIV Virus
This image is for representation purpose only.
Pharma major Lupin has received tentative approval for its Abacavir Sulfate and Lamivudine tablets from the USFDA to market generic version of ViiV Healthcare company's Epzicom tablets.
"Lupin's Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare company's Epzicom tablets, 600 mg/300 mg.
"Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection," a company statement said today.
The statement further said, "We have received tentative approval from USFDA for Abacavir Sulfate and Lamivudine tablets, to market a generic version of ViiV Healthcare company's Epzicom tablets."
Epzicom tablets had the US sales of USD 426 million.
The company is a significant player in cardiovascular, diabetology, asthma, paediatric and anti-infective space and holds global leadership position in the Anti-TB segment.
Recommended For You
- Porter's Son Thangarasu Natarajan: From Tennis Ball Star to IPL Big Bucks
- 2017 Audi A3 Facelift First Drive Review: The Future is Cylinder on Demand
- News18 Movie Awards 2017: Nominees For Best Singer (Male)
- Kangana, Shahid Promote Rangoon on TKSS: 5 Laugh Out Loud Moments
- Moto 3rd Anniversary Sale on Flipkart: Huge Discounts on Moto Z, Moto M and More